Literature DB >> 24414401

Recurrence of iris melanoma after proton beam therapy.

Maria T Sandinha1, Andrzej Kacperek, R Douglas Errington, Sarah E Coupland, Bertil Damato.   

Abstract

BACKGROUND/AIMS: A retrospective service evaluation to report on recurrence of iris melanoma after proton beam therapy (PBT).
METHODS: The cohort comprised 150 consecutive eyes with iris melanoma treated with proton beam radiotherapy. Treatment consisted of 53.1 Gy of proton beam irradiation delivered in four fractions over four consecutive days. Main outcome measures were local tumour control and tumour-related mortality.
RESULTS: A total of 150 patients were treated. The median follow-up time was 66 months (range, 12-108 months). The tumour ultrasound thickness ranged from 1.1 mm to 4.9 mm, with a median of 2.4 mm. The tumours in these patients had a median largest basal diameter of 6.7 mm (range, 2.9-8.4 mm), involving more than two clock hours of iris or angle in five patients. The ciliary body was involved in three patients. Eight patients (5.3%) presented with local recurrence, diagnosed after a median follow-up of 24 months (range, 12-84 months). The recurrence was focal in two patients and diffuse in six. Six eyes were enucleated whereas one eye underwent iridocyclectomy and one received a second course of PBT.
CONCLUSIONS: PBT provides excellent local tumour control and ocular preservation with good retention of vision. Most recurrences occur because the extent of the tumour is clinically underestimated but some tumours are radioresistant. Recurrence can occur several years after treatment. These findings indicate the need for wide safety margins and even radiotherapy of the entire anterior segment in patients with diffuse disease. Surveillance after treatment needs to be lifelong.

Entities:  

Keywords:  Iris melanomas; mortality; proton beam therapy; recurrence; treatment

Mesh:

Year:  2014        PMID: 24414401     DOI: 10.1136/bjophthalmol-2013-303321

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.

Authors:  Aline I Riechardt; Bettina Karle; Dino Cordini; Jens Heufelder; Volker Budach; Antonia M Joussen; Johannes Gollrad
Journal:  Strahlenther Onkol       Date:  2017-06-19       Impact factor: 3.621

Review 2.  Diffuse Iris Melanoma: Conservative Treatment with Proton Beam Therapy after Limbal Stem Cell Preservation or Enucleation?

Authors:  Alice Leblanc; Livia Lumbroso-Le Rouic; Laurence Desjardins; Rémi Dendale; Nathalie Cassoux
Journal:  Ocul Oncol Pathol       Date:  2019-03-20

3.  Iris melanoma relapsing sixteen years after proton-beam therapy: The importance of lifelong follow-up.

Authors:  Laetitia-Claire Msika; Laurence Desjardins; Vincent Cockenpot; Rémi Dendale; Olivier Berges; Khadija Aït Raïs; Gaëlle Pierron; Raymond L Barnhill; Nathalie Cassoux; Alexandre Matet
Journal:  Am J Ophthalmol Case Rep       Date:  2018-12-06

4.  Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma.

Authors:  Valerie Schmelter; Sarah Heidorn; Alexander Muacevic; Siegfried G Priglinger; Paul Foerster; Raffael Liegl
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.